Crystalline CDK Inhibitor Forms for Selective CDK2 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CDK inhibitors exhibit significant hematopoietic and gastrointestinal toxicities due to their inhibition of CDK1, while CDK2 activity is essential for certain cancer cells, necessitating a targeted approach to inhibit CDK2 without affecting CDK1.
Innovation Solution
Development of crystalline forms of CDK inhibitors, such as compounds of Formula (I) and their solvates, which exhibit improved aqueous solubility, stability, and ease of formulation, specifically targeting CDK2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-CDK inhibitors are used to inhibit CDK2 activity, then CDK2-mediated cancer cell proliferation is suppressed, but CDK1 inhibition causes significant hematopoietic and gastrointestinal toxicities
Solution Approach 1:
The patent segments the CDK inhibitor activity to specifically target CDK2 while sparing CDK1. This is achieved through the molecular structure of compounds of Formula (I), which are designed to selectively bind and inhibit CDK2 kinase activity without significantly affecting CDK1, thereby providing cancer cell proliferation control without the toxicities associated with pan-CDK inhibition
Solution Approach 2:
The patent applies local quality by creating a CDK inhibitor with selective affinity for CDK2. The molecular structure of compounds of Formula (I) is optimized to interact specifically with CDK2's active site and regulatory features, providing localized inhibition of CDK2-mediated processes in cancer cells while leaving CDK1-mediated essential cellular functions intact
2Stability of the object's composition
If crystalline forms of CDK inhibitors are developed, then aqueous solubility and stability are improved, but formulation complexity may increase
Solution Approach 1:
The patent applies parameter changes by developing specific crystalline forms (polymorphs) of the CDK inhibitor compounds. By controlling the crystal lattice arrangement and physical state of compounds of Formula (I), the invention achieves improved aqueous solubility and chemical stability without requiring complex formulation strategies, as the crystalline form itself provides the desired properties
Data Source
AI summary
The disclosure is in part directed to crystalline forms of (3R,5R)-5-(5-(3-(2,2-difluoroethoxy)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-3-yl)tetrahydrofuran-3-yl bicyclo[1.1.1]pentan-1-ylcarbamate, its solvates, its cocrystals, and variants thereof.